EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis

Haiyang Zhang iD, Ting Lu iD, Yinwei Li iD, Haixia Guan iD, Rebecca S Bahn iD, Huifang Zhou iD

Therapeutic Advances in Endocrinology and Metabolism · 2025-10 · 16

DOI: 10.1177/20420188251340137 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 28.05.2025. Verfasst von Haiyang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody that leads to immunosuppression through rapid depletion of B lymphocytes. It has been demonstrated to be useful in treating both thyroid eye disease (TED) and myasthenia gravis (MG), respectively. However, the effectiveness of RTX in concurrent TED and MG cases is unclear and not previously reported in the literature. In this study, we describe a 13-year-old girl who presented with a 10-year history of general MG and a 1-year history of Graves’ disease, bilateral proptosis, eye motility restriction, and lagophthalmos. A comprehensive evaluation confirmed the diagnosis of concurrent TED and MG. Satisfactory effectiveness was observed after RTX treatment without side effects. Based on the described observations, we suggest that RTX should be further explored as a treatment option for patients with concurrent TED and MG.

Schlagwörter

Stichwörter der Autor:innen

myasthenia gravispediatricsrituximabthyroid eye disease

Autor:innen und Institutionen

  • State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Consultant Emerita Division of Endocrinology, Professor of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.
  • State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai 200011, China.

ORCID-Profile: Haiyang Zhang, Ting Lu, Yinwei Li, Haixia Guan, Rebecca S Bahn, Huifang Zhou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Lu, T., Li, Y., Guan, H., Bahn, R. S., & Zhou, H. (2025). Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. Therapeutic Advances in Endocrinology and Metabolism, 16. https://doi.org/10.1177/20420188251340137

Vancouver

Zhang H, Lu T, Li Y, Guan H, Bahn RS, Zhou H. Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. Therapeutic Advances in Endocrinology and Metabolism. 2025;16. doi:10.1177/20420188251340137

BibTeX
@article{Zhang2025,
  author = {Zhang, Haiyang and Lu, Ting and Li, Yinwei and Guan, Haixia and Bahn, Rebecca S and Zhou, Huifang},
  title = {Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis},
  journal = {Therapeutic Advances in Endocrinology and Metabolism},
  year = {2025},
  volume = {16},
  doi = {10.1177/20420188251340137}
}
Kostenlos starten →